Ensign Peak Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ensign Peak Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-233,221	Closed	-$26.1M	–	2249
2021 Q4	$26.1M	Sell	233,221 -66,779	-22%	-$8.05M	0.05%	272
2021 Q3	$37.7M	Buy	+300,000	New	+$38.6M	0.08%	207
2020 Q4	–	Sell	-24,649	Closed	-$2.75M	–	1883
2020 Q3	$2.75M	Buy	+24,649	New	+$2.76M	0.01%	808

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Ensign Peak Advisors's XBI Position: Q1 2022 in Review

Ensign Peak Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 233,221 shares — an estimated $26.1M sold.

Ensign Peak Advisors first reported a position in XBI in Q3 2020 and held it in 3 quarters. The position peaked at $37.7M in Q3 2021. 702 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

Ensign Peak Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
Ensign Peak Advisors sold 233,221 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $26.1M.
Ensign Peak Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and held it in 3 quarters.
Ensign Peak Advisors's State Street SPDR S&P Biotech ETF position peaked at $37.7M in Q3 2021.
702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Ensign Peak Advisors's 13F filing for Q1 2022, filed 16 May 2022.